Cambridge Healthtech Institute’s Sixteenth Annual
Engineering Antibodies
New Science and Technologies for the Selection, Engineering and Targeting of the Next Generation of Antibody Therapeutics
Part of the 11th Annual PEGS: the essential protein engineering summit
May 6-7, 2015 | Seaport World Trade Center | Boston, Ma

The field of protein engineering is at an exciting point in its development, with new generations of therapeutic antibodies now reaching the market, great advances in protein science and a body of clinical evidence that can be used to inform the development of safe, highly effective therapies for unmet medical needs. At PEGS, Engineering Antibodies presents the state of the art in technologies used by protein engineers working at the discovery and design stage to quickly and efficiently craft biotherapeutics directed at the most elusive targets and biological functions. Emphasis will be given to new presentations that highlight unpublished work in this important field.

KEYNOTE PRESENTATION: NGS and Computational Motif Analysis to Identify the Antibody Epitope Specificities that Co-Associate with a Disease Phenotype

Patrick Daugherty, Ph.D., Professor, Chemical Engineering, Biomolecular Science and Engineering, University of California, Santa Barbara


A Monoclonal Antibody that Targets a NaV1.7 Channel Voltage Sensor for Pain and Itch Relief

Ru-Rong Ji, Ph.D., Professor, Department of Anesthesiology and Neurobiology, Duke University Medical Center

Rapid Development of Antibody Therapeutics for Infectious Disease Outbreaks

Wayne A. Marasco, M.D., Ph.D., Professor, Medicine, Harvard Medical School

Antibody Therapeutics for CNS Diseases and Delivery across the Blood Brain Barrier

George Thom, Senior Scientist, Antibody Discovery and Protein Engineering, MedImmune

Phage Display Derived Calcium-Dependent Biparatopic Antibody for Eliminating High Plasma Concentration Target Antigen

Shinya Ishii, Research Scientist, Research Division, Chugai Pharmaceutical Co., Ltd., Japan


Single-Cell Sequencing and Analysis in Antibody Discovery

J. Christopher Love, Ph.D., Associate Professor, Chemical Engineering, Koch Institute, Massachusetts Institute of Technology

Multiplexing Technology to Measure the Specificity of Antibody Binding

Jonas V. Schaefer, Ph.D., Head, High-Throughput Laboratory, Department of Biochemistry, University of Zurich, Switzerland

A Pipeline for the Discovery of immunoPCR Reagents

Andrew Ellington, Ph.D., Research Professor of Biochemistry, University of Texas, Austin

Enhanced IgG Hexamerization Mediates Efficient C1q Docking and More Rapid and Substantial Complement-Dependent Cytotoxicity (CDC): Preclinical Proof-of-Concept

Janine Schuurman, Ph.D., Vice President, Research, Genmab, Denmark

Creating Focused Mutant Libraries for Protein Engineering

Alain Ajamian, Ph.D., Director, Chemical Computing Group

Michael Drummond, Ph.D., Applications Scientist, Chemical Computing Group


Computational Design of Protein Antigens

William R. Schief, Ph.D., Professor, Immunology and Microbial Science, The Scripps Research Institute

OptMAVEn: De novo Design of Antibody Variable Regions

Costas D. Maranas, Ph.D., Professor, Chemical Engineering, Pennsylvania State University

SPECIAL PRESENTATION: Current Intellectual Property Developments in Antibody Engineering

Konstantin M. Linnik, Ph.D., Partner, Intellectual Property, Nutter, McClennen & Fish, LLP


NGS-Based Characterization of Antibody Responses Following Vaccination

Sai Reddy, Ph.D., Assistant Professor, Biosystems Science and Engineering, ETH Zurich, Switzerland

Ligand Discovery for T Cell Receptors Using Yeast Display

Michael Birnbaum, Researcher, Stanford University School of Medicine

Case Studies of Approaches for Efficiently Mining the Natural Antibody Repertoire

Daniel Lightwood, Ph.D., Director, Antibody Discovery, UCB-Celltech, United Kingdom

Realizing the Therapeutic Potential of Antibodies Derived from a Human Immune Response – Case Studies in Indications of Oncology and Infectious Disease

Kristine Swiderek, Ph.D., CSO, Theraclone Sciences

For more details on the conference, please contact:
Kent Simmons
Program Director
Cambridge Healthtech Institute
Phone: 207-869-9199

For partnering and sponsorship information, please contact:
Jason Gerardi (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: 781-972-5452

Carol Dinerstein (Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: 781.972.5471